What is Zacks Research’s Estimate for IRWD FY2025 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities researchers at Zacks Research lifted their FY2025 EPS estimates for Ironwood Pharmaceuticals in a research report issued on Wednesday, February 12th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings of $0.31 per share for the year, up from their prior forecast of $0.17. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2025 earnings at $0.20 EPS and FY2026 earnings at $0.35 EPS.

A number of other equities research analysts have also recently commented on IRWD. Craig Hallum reduced their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. StockNews.com cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, JMP Securities reduced their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.60.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD opened at $1.92 on Monday. The firm has a fifty day moving average price of $3.54 and a 200 day moving average price of $4.08. Ironwood Pharmaceuticals has a 1-year low of $1.59 and a 1-year high of $15.65. The stock has a market cap of $307.26 million, a PE ratio of -64.00 and a beta of 0.29.

Insider Transactions at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CMO Michael Shetzline sold 41,269 shares of the company’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the transaction, the chief marketing officer now owns 554,007 shares in the company, valued at $975,052.32. The trade was a 6.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 192,381 shares of company stock worth $338,591 over the last ninety days. 12.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pacer Advisors Inc. grew its position in Ironwood Pharmaceuticals by 4.0% during the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock worth $51,967,000 after buying an additional 450,949 shares during the period. State Street Corp grew its position in Ironwood Pharmaceuticals by 7.3% during the third quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company’s stock worth $40,870,000 after buying an additional 677,024 shares during the period. Renaissance Technologies LLC grew its position in Ironwood Pharmaceuticals by 5.5% during the fourth quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company’s stock worth $40,163,000 after buying an additional 469,043 shares during the period. Geode Capital Management LLC grew its position in Ironwood Pharmaceuticals by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company’s stock worth $14,652,000 after buying an additional 13,028 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Ironwood Pharmaceuticals by 4.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company’s stock worth $8,786,000 after buying an additional 78,969 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.